CapsoVision, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by CapsoVision, Inc. on March 13, 2026. The filing reports the entry into a material definitive agreement amendment with Canon Inc. regarding the development of CMOS image sensors for capsule endoscopy applications.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, or liquidity metrics. The only specific financial data disclosed relates to the amended development agreement:
- Total Development Fee: Increased to approximately $5.1 million (original $4.1 million plus $1.0 million increase).
- Initial Fee: $1.0 million paid in cash upon effectiveness.
- Remaining Development Fee: Approximately $4.1 million, to be paid over time via an additional amount added to the unit price of future CMOS image sensor purchases.
Material Changes
On March 9, 2026, CapsoVision amended its original development agreement with Canon Inc. (originally reported on July 15, 2025). The material change is an increase in the total development fee by $1.0 million due to increased features in the sensor specifications. The remaining development fee obligation was adjusted accordingly, while the "Additional Amount" per unit and other terms remain unchanged.
Outlook, Risks, and Management Commentary
The agreement facilitates the evaluation of functionality and performance of Canon image sensors and the conduct of clinical evaluations to obtain FDA 510(k) clearance. The filing notes that the remaining development fee is contingent upon the delivery of a specified number of CMOS image sensors meeting agreed specifications within the required timeframe. Upon such delivery, the parties are expected to enter into a master purchase agreement for a minimum number of sensors.
Key Facts for Investor Verification
- Verify the total committed capital outlay for the Canon development agreement is now approximately $5.1 million.
- Confirm the company's current cash position to ensure it can meet the $1.0 million initial fee and future unit price adjustments.
- Monitor the timeline for the delivery of specified CMOS image sensors, as this triggers the master purchase agreement and ongoing fee payments.
- Track progress toward FDA 510(k) clearance for capsule endoscopies incorporating these sensors.